Elevated Phospholipase A2 Activities in Plasma Samples from Multiple Cancers

Hui Cai1,2, Elena G. Chiorean3, Michael V. Chiorean3, Douglas K. Rex3, Bruce W. Robb3, Noah M. Hahn3,4, Ziyue Liu5, Patrick J. Loehrler3, Marietta L. Harrison6, Yan Xu1*

1 Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, Indiana, United States of America, 2 Department of Thoracic Oncosurgery, First Affiliated Hospital of Xian Jiaotong University, Xian, People’s Republic of China, 3 Department of Medicine, Indiana University Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana, United States of America, 4 Hoosier Oncology Group, Indianapolis, Indiana, United States of America, 5 Department of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana, United States of America, 6 Medicinal Chemistry and Molecular Pharmacology, Oncological Sciences Center, Purdue University Center for Cancer Research, West Lafayette, Indiana, United States of America

Abstract

Only in recent years have phospholipase A2 enzymes (PLA2s) emerged as cancer targets. In this work, we report the first detection of elevated PLA2 activities in plasma from patients with colorectal, lung, pancreatic, and bladder cancers as compared to healthy controls. Independent sets of clinical plasma samples were obtained from two different sites. The first set was from patients with colorectal cancer (CRC; n = 38) and healthy controls (n = 77). The second set was from patients with lung (n = 95), bladder (n = 31), or pancreatic cancers (n = 38), and healthy controls (n = 79). PLA2 activities were analyzed by a validated quantitative fluorescent assay method and subtype PLA2 activities were defined in the presence of selective inhibitors. The natural PLA2 activity, as well as each subtype of PLA2 activity was elevated in each cancer group as compared to healthy controls. PLA2 activities were increased in late stage vs. early stage cases in CRC. PLA2 activities were not influenced by sex, smoking, alcohol consumption, or body-mass index (BMI). Samples from the two independent sites confirmed the results. Plasma PLA2 activities had approximately 70% specificity and sensitivity to detect cancer. The marker and targeting values of PLA2 activity have been suggested.

Introduction

Cancer is one of the major health burdens worldwide. More than 1.6 million new cancer cases and over 577,000 deaths from cancer are projected to occur in the United States in 2012 [1]. Lung cancer (LC) and colorectal cancer (CRC) are among the most frequent types of cancers. Pancreatic and bladder cancers count for (3–7% of all cancers), but pancreatic cancer (PC) is one of the deadliest cancers, with a dismal 5-year survival rate of 6% [1]. The success of current cancer treatments depends strongly on the time of diagnosis, with early detection and identification of high risk patient populations resulting in the most favorable overall survivals in these diseases [1,2]. It is expected that early detection and screening of high risk patient populations may have the most significant impact on altering overall survival in these diseases. Thus, there is an urgent need for efficient and sensitive early detection methods [3]. While imaging-based detection methods, including spiral computerized axial tomography (CT) and colonoscopy are effective early detection methods for LC and CRC, respectively [4], they are rather expensive and inconvenient. In addition, modern imaging techniques have a high incidence of discovery of lung nodules, many of which are falsely positive, but still calling for additional and sometimes painful examinations [5]. Molecular approaches to cancer diagnosis through biomarkers measured by non-invasive means could significantly improve the specificity and sensitivity of cancer detection [5]. In particular, serological biomarkers may be the most useful in early detection due to the minimal invasiveness, cost-effectiveness, and convenience. Moreover, serological biomarkers identifying novel cancer-related genes and/or molecules may provide new insight into the biology of cancers and may also become attractive targets for treatment [3].

Phospholipase A2 enzymes (PLA2s) are the major enzymes producing the cyclooxygenase-2 (COX-2) substrate, arachidonic acid (AA), as well as lysophospholipids. Both of these classes of products are signaling molecules involved in cancers. However, only in recent years have PLA2s emerged as cancer targets [6]. More than 30 enzymes that possess PLA2 or related activity have been identified in mammals [7]. They are divided into four groups based on their cellular localization, substrate specificity, and calcium-dependence [8], including cytosolic (cPLA2α), calcium-independent (iPLA2), secreted (sPLA2), and lipoprotein-associated...
PLA₂ (Lp-PLA₂). In cancer, most of the attention has been focused on sPLA₂ and cPLA₂ [8]. We and others have shown that iPLA₂ is functionally involved in promoting the development of ovarian cancer (OC) and other cancers, in vitro and in vivo [9–13]. sPLA₂ and Lp-PLA₂ are secreted enzymes. In contrast, both cPLA₂ and iPLA₂ are cytosolic enzymes and their extracellular existence has only been shown to be related to exosomes from RBL-2H3 cells (a mast and basophil cell line) [14]. Exosomes are 40–100 nm diameter membrane vesicles released from multivesicular bodies by intact cells and are known to participate in intercellular signaling [15]. We have recently detected extracellular- and exosome-free iPLA₂ and cPLA₂ activities in ascites and tissues from OC patients [16].

In the current work we have focused on PLA₂ activities rather than expression of individual PLA₂ enzymes and examined PLA₂ activities in blood plasma samples from patients with different cancers, in comparison with those from healthy controls. We used our recently validated quantitative, convenient, highly reproducible PLA₂ assay method [16] and showed for the first time that plasma PLA₂ activities from patients with CRC, LC, PC, and bladder cancer (BC) were significantly higher than those of healthy controls. These activities were correlated with tumor stages in CRC. Other potential influential factors, including sex, age, smoking and alcohol consumption were also examined in this study.

Materials and Methods

Human sample collection and processing

Two sets of independently collected clinical plasma samples were obtained for this study. The first set from the Indiana University School of Medicine (IUSM) focused on CRC patients and healthy controls screened by colonoscopy and found negative for adenomatous polyps and CRC. Blood samples collected in the presence of EDTA were centrifuged at 1,750 g for 15 min at 15–24°C, aliquoted in siliconized Eppendorf tubes and stored at −80°C. The second set of samples was from patients with lung, bladder, or pancreatic cancers, as well as healthy controls. These samples were collected by the Hoosier Oncology Group (HOG) in Indianapolis, IN as part of the study entitled, “A Biological Sample Collection Protocol of Patients with and without Metastatic Solid Organ Malignancies: Hoosier Oncology Group Study BANK09-138”. Blood samples were centrifuged at 3,500 rpm for 30 min. The aliquoted samples were stored at −70°C. HOG is a non-profit medical research organization. Although it is a separate entity, IUSM is a supporting organization for board appointments and IRB approvals for HOG. Three separate IRB protocols for collecting and/or use the blood samples related to this work have been approved by the same IUSM Institutional Review Board (Protocol numbers: 0670-81, 0808-24, 0905-20). Written informed consent forms were obtained from all subjects and all clinical investigation had been conducted according to the principles expressed in the Declaration of Helsinki.

Table 1. Demographic data for participants from IUSM and HOG study.

|                          | Age (years) | Sex (%) | Race (%) |
|--------------------------|-------------|---------|----------|
|                          | No. Mean SD | Male    | Female   | P value | White | African American | Others | P value |
| Participants from IUSM   |             |         |          |         |       |                 |        |         |
| Healthy                  | 77          | 51.6    | 13.5     | 10.0    | 0.01075 | 89.6              | 9.1    | 1.3     |
| CRC                      | 38          | 56.0    | 13.4     | 0.0175  | 44.7   | 55.3              | 0.6470 | 86.8    | 5.3     | 7.9    | 0.4501 |
| Participants from HOG    |             |         |          |         |        |                 |        |         |
| Healthy                  | 79          | 42.7    | 12.0     | 0.0100  | 77.2   | 22.8              | 0.893  | 2.7     | 8.0     |
| LC                       | 95          | 63.2    | 9.5      | <0.0001 | 64.2   | 35.8              | 0.0621 | 89.5    | 8.4     | 2.1    | 0.0654 |
| BC                       | 31          | 70.5    | 10.0     | <0.0001 | 87.1   | 12.9              | 0.2438 | 93.6    | 6.5     | 0.0    | 0.1868 |
| PC                       | 38          | 68.7    | 8.7      | <0.0001 | 63.2   | 36.8              | 0.1102 | 92.1    | 5.3     | 2.6    | 0.4327 |

CRC: colorectal cancer; LC: Lung cancer; BC: Bladder cancer; PC: Pancreatic cancer; SD, standard deviation; HOG: Hoosier Oncology Group.

In the HOG set: • For gender, the overall P value is 0.0339. • For Age, the overall P value is <0.0001. • For race, the overall P value is 0.2352. Since it was not significant, it was not recommended to perform pair-wise comparisons. Nonetheless, P values for pair-wise comparisons are given to be consistent with the other two variables. All pair-wise comparisons are against healthy controls. doi:10.1371/journal.pone.0057081.t001

Reagents and inhibitors

The PLA₂ substrate 1-O-(6-Dabcyl-Aminohexanoyl)-2-O-(6-(12-BODIPY-Dodecanoyl) Aminohexanoyl)-sn-3-Glyceryl Phosphatidylcholine (DBPC) was from Echelon Bioscience (Salt Lake City, UT, USA). Bromoelanol lactone (BEL) and methyl arachidonoyl-nitrofluorophosphonate (MAFP) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

PLA₂ enzymatic activity analyses

PLA₂ activities were analyzed using the fluorescent substrate DBPC, a fluorogenic phosphatidylcholine substrate [17]. Plasma samples (0.1 μL) were mixed with DBPC (0.2 μg in PBS) to final volume 200 μL. The fluorescence was read at intervals over several hours on a Victor IV plate reader (Perkin Elmer, Waltham, MA, USA). PLA₂ activities were expressed as change in fluorescence intensity/min/μL of plasma. As previously described [16], we selected conditions to distinguish PLA₂ activity derived from different subtypes: a) the “natural” PLA₂ activity without any exogenous additives, b) the iPLA₂ activity in the presence of 5 mM EDTA (a divalent cation chelator to block all PLA₂s requiring calcium, including sPLA₂ and cPLA₂), c) the sPLA₂ activity in the presence of 1.2 mM calcium chloride (the natural ionized calcium concentration in blood [18]) and MAFP (10 μM, a dual inhibitor of cPLA₂ and iPLA₂), and d) the cPLA₂ activity in the presence of 100 μM calcium chloride and bromoelanol lactone (BEL, 10 μM, a selective inhibitor for iPLA₂).
Statistical Analysis
Categorical variables were summarized as counts with percentages and continuous variables were summarized as means with standard deviations (SD) across the healthy control, and cancer groups. The Chi-square test was used to test the associations between disease statuses and categorical covariates such as sex, race, smoking, and alcohol drinking. For continuous covariates such as age and BMI, one-way ANOVA was used to test the overall difference and Student t-test was used to test the pair-wise difference across disease statuses. Linear regression was used to assess the univariate association between PLA2 measurements and...
covariates. Logistic regression was used to evaluate the classification performance of PLA2 measurements. Bootstrap was used to internally validate the classification performance using 1000 samples [19]. Each sample had the same size as the original data set and was used to develop the model. The results were then tested in the original data. Areas under the curve (AUCs) were calculated for each repeat. All tests were two-sided. Given the exploratory nature of this study, no adjustments for multiple comparisons were adopted. P values <0.05 were considered to be statistically significant. All analyses were performed using SAS software Version 9.3 (SAS Institute Inc., Cary, NC, USA).

Results

Subject demographic data

The demographic data for the study participants are summarized in Table 1. For the IUSM CRC set samples, 41.7% of the overall participants were male, 88.7% were white, and the mean age was 53.1 years. The age, sex, and race composition were not significantly different in control vs. CRC groups (P values >0.05; Table 1). For the second set of samples, the age in the healthy control group was significantly younger than each of the three cancer groups (Table 1). Although males were dominant in each group, they were not significantly different from the second set of healthy controls. 71.2% of the overall participants were male, 90.4% were white, and the mean age was 50.3 years (Table 1).

Reproducibility and stability of the PLA2 assays

We have recently validated the quantitative nature of the DBPC-based PLA2 assays and optimized the conditions for biological fluids and tissues samples [16]. When each of 8 representative plasma samples were analyzed three times, the PLA2 activity values reproducible, with an average standard deviation (SD) 13.5 (1.3%). We also tested the PLA2 activity stability by comparing them in samples before storage to those in the same samples stored at −80°C for one month, as well as the effect of freeze-and-thaw on the PLA2 activities in 8 representative samples. As previously reported [16], PLA2 activities were stable with SDs <35.8 (5.8%). In addition, we showed that in the presence of all other assay components including inhibitor(s) used in this study, but in the absence of blood or other biological samples, the non-specific hydrolysis of the DBPC substrate was negative and negligible (data not shown).

The natural PLA2, cPLA2, iPLA2, and sPLA2 activities were elevated in cancer samples vs. healthy controls

Blood iPLA2 and cPLA2 activities have not been previously reported in human samples. We analyzed the natural PLA2 (defined as the PLA2 activities measured under the conditions without any modifiers, which may be lower than the sum of the subgroup PLA2 activities measured under modified conditions), as well as cPLA2, iPLA2, and sPLA2 activities in plasma samples. Except for the healthy vs. CRC cPLA2 activity, all other comparisons showed that PLA2 activities were significantly elevated in the cancer groups (Fig. 1A and 1B). PLA2 activity values across plasma samples from LC, BC, and PC patients were not significantly different (P values >0.05).

Since sPLA2 is secreted, it was expected that sPLA2 activity would account for the major portion of the PLA2 activity detected in the blood. However, in our results, high levels of iPLA2 and cPLA2 and low levels of sPLA2 activities were observed in all plasma samples. Blood exosomes may be the carriers of these activities [15]. We used differential centrifugation steps as we described recently [16] to determine whether these activities could

Table 2. Clinical characteristics and PLA2 activities in the CRC cases.

| No. | PLA2 | Mean | SD | P value | iPLA2 | Mean | SD | P value | cPLA2 | Mean | SD | P value | sPLA2 | Mean | SD | P value |
|-----|------|------|----|--------|------|------|----|--------|------|------|----|--------|------|------|----|--------|
| Primary site | | | | | | | | | | | | | | | | |
| Colon | 24  | 1412.3 | 473.75 | | 1302.8 | 428.78 | | 1424.0 | 480.16 | | 476.3 | 199.33 | | | | |
| Rectum | 14  | 1348.0 | 460.33 | | 1254.7 | 428.33 | | 1347.7 | 489.95 | | 408.3 | 195.50 | | | | |
| Previous treatment | | | | | | | | | | | | | | | | |
| Surgery only | 7  | 1340.3 | 382.29 | | 1193.1 | 286.55 | | 1303.4 | 424.30 | | 435.5 | 92.75 | | | | |
| CT and RT | 3  | 1614.8 | 542.80 | | 1599.5 | 626.64 | | 1755.4 | 707.50 | | 495.9 | 219.34 | | | | |
| Surgery and CT | 10  | 1496.8 | 596.54 | | 1399.5 | 543.97 | | 1521.1 | 633.55 | | 519.8 | 264.44 | | | | |
| Surgery, CT and RT | 5  | 1459.0 | 437.46 | | 1402.9 | 322.07 | | 1511.8 | 322.27 | | 472.8 | 200.95 | | | | |
| Untreated | 13  | 1252.2 | 404.71 | | 1128.6 | 341.99 | | 1221.8 | 327.50 | | 388.5 | 183.68 | | | | |

*Student t-test.
**One-way ANOVA.

CT: chemotherapy; RT: radiotherapy.

doi:10.1371/journal.pone.0057081.t002

Figure 2. PLA2 activities were higher in late stage CRC samples.

The natural and individual groups of PLA2 activities were progressively increased by tumor stage. Stage I and II (n = 7), Stage III and IV (n = 31). 

![Image](58x31 to 293x730)

Elevation of Plasma PLA2 Activity in Cancers

![Diagram](58x31 to 293x730)
be associated with platelets, exosomes, or other microvesicles. Two blood samples were first centrifuged at 1,750 g for 15 min to remove most blood cells and the supernatant was termed S1. S1 was centrifuged at 20,000 g for 20 min, which resulted in S2 and the pellet (P2; cell fragments and large vesicles). S2 was ultracentrifuged at 110,000 g for 2 hr, which resulted in S3 and P3 (exosomes). A final centrifugation of S3 at 200,000 g for 2 hr resulted in S4 and P4 (other microvesicles). We found that all PLA2 activities were retained in the S1 through S4 fractions, suggesting they were "free" and not associated with microvesicles (detailed data not shown). This is similar to what we have recently reported in human ovarian cancer ascites and novel secretion mechanisms for iPLA2s and cPLA2s may be involved [16].

Clinical parameters and PLA2 activities in cancer plasma samples

Interestingly, the natural, iPLA2, and sPLA2 activities in plasma of CRC patients were increased in subjects with late stages (III and IV) as compared to earlier stage (I and II) disease (*P* = 0.0335, 0.0367, 0.0778, and 0.0345 for PLA2, iPLA2, cPLA2, and sPLA2, respectively; Fig. 2), suggesting that these enzymatic activities may be involved in CRC progression. We compared the PLA2 activities in colon (n = 24) vs. rectal (n = 14) samples. Even though the nature, as well the sub-group PLA2 activities in colon cancer patients were higher than those from rectal cancer patients, the differences were not statistically significant (*P* > 0.05 in all cases; Table 2). In addition, no difference was found in PLA2 activities

| Table 3. Clinical characteristics and PLA2 activities in the LC, BC, and PC cases. |
|-----------------------------------------------|
| **PLA2** | **iPLA2** | **cPLA2** | **sPLA2** |
| No. | Mean | SD | *P* value | Mean | SD | *P* value | Mean | SD | *P* value |
| Lung cancer | | | | | | | | | |
| T stage | 0.4760** | 0.5001** | 0.4960** | 0.6129** |
| T1 | 19 | 1714.2 | 548.5 | 1626.6 | 514.2 | 2190.2 | 752.6 | 457.1 | 280.7 |
| T2 | 21 | 1569.3 | 671.8 | 1490.6 | 640.6 | 1924.1 | 754.0 | 478.7 | 261.4 |
| T3 | 9 | 1437.9 | 479.0 | 1374.7 | 460.7 | 1721.3 | 480.5 | 356.2 | 166.6 |
| T4 | 35 | 1803.5 | 878.2 | 1691.8 | 823.9 | 2141.7 | 1105.9 | 471.5 | 228.4 |
| N stage | 0.9973** | 0.9685** | 0.9758** | 0.8009** |
| N0 | 14 | 1626.7 | 566.2 | 1559.5 | 522.6 | 2061.3 | 584.4 | 386.3 | 143.2 |
| N1 | 11 | 1574.8 | 508.1 | 1442.7 | 479.8 | 1960.3 | 671.2 | 404.1 | 200.4 |
| N2 | 21 | 1613.9 | 643.7 | 1524.1 | 631.4 | 1961.6 | 883.6 | 431.4 | 222.9 |
| N3 | 29 | 1604.2 | 671.7 | 1510.2 | 620.6 | 1944.3 | 888.0 | 454.8 | 270.0 |
| Bladder cancer | | | | | | | | | |
| T stage | 0.7482** | 0.7320** | 0.5790** | 0.1793** |
| Tis | 2 | 1736.6 | 429.9 | 1568.4 | 406.3 | 2046.9 | 355.0 | 395.2 | 119.1 |
| T1 | 4 | 1326.0 | 525.4 | 1306.3 | 517.3 | 1717.4 | 525.6 | 299.2 | 222.9 |
| T2 | 10 | 1833.5 | 832.3 | 1710.5 | 759.0 | 2207.7 | 1074.9 | 451.0 | 160.6 |
| T3 | 7 | 1812.3 | 522.3 | 1834.5 | 506.3 | 2541.3 | 630.6 | 444.4 | 141.7 |
| T4 | 8 | 1800.7 | 582.9 | 1630.9 | 544.2 | 2084.8 | 638.9 | 596.2 | 263.3 |
| N stage | 0.8224** | 0.7579** | 0.7786** | 0.1010** |
| N0 | 10 | 1665.1 | 479.6 | 1535.2 | 446.2 | 2158.4 | 619.1 | 436.1 | 168.2 |
| N1 | 5 | 1602.0 | 482.3 | 1549.8 | 507.6 | 1872.4 | 726.4 | 411.2 | 173.2 |
| N2 | 8 | 1813.4 | 964.3 | 1806.0 | 881.1 | 2333.5 | 1107.6 | 400.4 | 180.1 |
| N3 | 5 | 1937.5 | 428.0 | 1761.7 | 394.4 | 2135.4 | 234.1 | 671.9 | 287.7 |
| Pancreatic cancer | | | | | | | | | |
| T stage | 0.7748** | 0.8479** | 0.8488** | 0.8453** |
| T1 | 1 | 1398.3 | 1294.2 | 1204.7 | 419.7 |
| T2 | 12 | 1823.2 | 708.6 | 1730.9 | 647.8 | 2413.7 | 897.1 | 476.3 | 139.5 |
| T3 | 8 | 2031.6 | 1477.7 | 1891.1 | 1421.5 | 2693.9 | 2009.0 | 556.0 | 286.2 |
| T4 | 15 | 2279.0 | 1509.8 | 2077.8 | 1423.9 | 2741.7 | 1919.3 | 595.7 | 506.3 |
| N stage | 0.1928* | 0.1448* | 0.1243* | 0.0671* |
| N0 | 9 | 2663.9 | 1855.8 | 2564.3 | 1749.6 | 3475.3 | 2290.2 | 699.2 | 377.1 |
| N1 | 19 | 1756.4 | 837.8 | 1598.2 | 738.6 | 2133.6 | 964.7 | 428.6 | 152.1 |

*Student t-test.*  
**One-way ANOVA.

doi:10.1371/journal.pone.0057081.t003
among different subgroups of CRC patients with previous treatments (surgery, chemotherapy, radiotherapy, or untreated; Table 2). In contrast, we found that PLA2 activities were not correlated to either T or N stages of LC, BC, or PC (Table 3).

Impact of other factors on PLA2 activity

We have collected other factors, which might influence PLA2 activities, including smoking, alcohol consumption, and body-mass index (BMI). For the CRC study, from the 80 subjects with available smoking information (27 CRC and 53 healthy cases), the majority (96%) of people did not smoke when the samples were collected, with an average 50.5% people never smoked and 45.7% of past smoker, and only 9.4% and 19.2% people had second hand smoking exposure in each group. The smoking statuses were similarly distributed in the two groups ($P$ values $>0.05$; detailed data in Table 4) and there were no statistical differences in PLA2 activities among different smoking statuses (Fig. 3A). In the second set of study, the smoking statuses were significantly different between healthy controls and each of the cancer groups with higher percentages of people who were current, past, or second-hand smokers in cancer groups ($P$ values $<0.05$, except in one comparison, Table 5). Nevertheless, no statistical differences were observed in the PLA2 activities among different smoking statuses,

Table 4. Smoking, alcohol consumption, and the BMI status of participants from IUSM*.

| Smoking status | Healthy | CRC |
|----------------|---------|-----|
|                | No. | %  | No. | %  | P value |
| Current smoker | 2  | 3.8 | 1  | 3.7 | 0.4609 |
| Past smoker    | 18 | 34.0 | 13 | 48.2 |       |
| Never smoked   | 33 | 62.3 | 13 | 48.2 |       |
| Second hand smoke |    |       |    |       |
| No             | 48 | 90.6 | 21 | 80.8 | 0.2185 |
| Yes            | 5  | 9.4  | 5  | 19.2 |       |
| Alcohol        |    |       |    |       |
| No             | 6  | 11.3 | 1  | 3.7  | 0.2542 |
| Yes            | 47 | 88.4 | 26 | 96.3 |       |
| BMI (Mean ± SD) | 28.2±6.96 | 25.4±4.01 | 0.0272 |

*These data are available from a subset of the participants.

doi:10.1371/journal.pone.0057081.t004
supporting the concept obtained from the first set of study that plasma PLA2 activities are not affected by smoking (Fig. 3B).

Alcohol consumption in the control and CRC groups were not significantly different (Table 4). The alcohol consumers in the CRC groups tend to have higher levels of plasma PLA2 activities, but the differences were not statistically significant (Fig. 4). However, due to the low numbers in non-alcohol consumption group (n = 7), we should interpret these data with caution. For other cancers, similar results were obtained. Although there were significant higher percentages of alcohol consumption subjects in other cancers, similar results were obtained. Although there were differences in PLA2 activities in the older subjects (Fig. 7A), although the mean BMI in the CRC and PC groups were significantly less than those in control groups (Tables 4 and 5), the PLA2 activities were not significantly related to alcohol (Fig. 5).

The classification performance of plasma PLA2 activities

Logistic regression was used to evaluate the classification performance of PLA2 activities in cancers. All four PLA2 measurements were kept as predictors regardless of their significance. The classification performances were summarized by receiver operating characteristic (ROC) curves (Fig. 8). Prediction formulas were generated using the parameter estimates.

The prediction formula to separate CRC cases from healthy subjects is:

$$\ln\left(\frac{P_{CRC}}{1-P_{CRC}}\right) = -2.7372 + 0.00329 \times PLA2 - 0.00286 \times cPLA2 + 0.00362 \times iPLA2 + 0.00344 \times sPLA2$$

where “P_{CRC}” stands for the probability of having CRC. The ROC curve shown in Fig. 8A has an area under the curve (AUC) = 0.7502.

Since external validations would require an independent study, we instead adopted internal methods to validate the classification performances. Among different internal validation methods, it has been shown that bootstrap outperforms jackknife, cross-validation and data-splitting methods [19]. Therefore, bootstrap was adopted for validation. In particular, the prediction formula was obtained by fitting the same model for each bootstrapped sample. The formula was applied to the original data to calculate the prediction probabilities. The performance for this particular bootstrap sample was summarized by AUC of the ROC curve. The overall performance was evaluated by summarizing AUCs across 1,000 bootstrapped samples. In 95% of the 1,000 bootstrapped samples, AUCs are higher than 0.7145 for CRC vs. healthy. Therefore, these results internally confirm the classification performances of the models developed above.

The prediction formula and the ROC curve to separate all cancer cases from healthy subjects in the second set of study are as follows and shown in Fig. 8B, with an AUC = 0.8337.
This performance was validated in 1000 bootstrapped samples. In 95% of the 1000 bootstrapped samples, AUCs are higher than 0.8205 for LC, PC, BC combined vs. the second set of healthy controls.

The prediction formulas and the ROC curves for the separate LC, PC, and BC cases from healthy subjects in the second set of studies are listed below and Figs. 8C to 8E, with AUCs $>0.811$, indicating good classification performances of the tests. For LC versus healthy control, the AUC = 0.8119 (Fig. 8C). In 95% of the 1000 bootstrapped sample, AUCs are higher than 0.7923.

$$\ln \left( \frac{P}{1-P} \right) = -2.6398 - 0.00035 \times PLA_2 - 0.00169 \times iPLA_2 + 0.00311 \times cPLA_2 + 0.00276 \times sPLA_2$$

This performance was validated in 1000 bootstrapped samples. In 95% of the 1000 bootstrapped samples, AUCs are higher than 0.8205 for LC, PC, BC combined vs. the second set of healthy controls.

The prediction formulas and the ROC curves for the separate LC, BC, and PC cases from healthy subjects in the second set of studies are listed below and Figs. 8C to 8E, with AUCs $>0.811$, indicating good classification performances of the tests. For LC versus healthy control, the AUC = 0.8119 (Fig. 8C). In 95% of the 1000 bootstrapped sample, AUCs are higher than 0.7923.

**Figure 4. The influence alcohol consumption on plasma PLA2 activities.** Comparison of PLA2 activities between "non-alcohol" and "alcohol" groups with the healthy and CRC participants. A. Comparison of PLA2 activities between "non-alcohol" and "alcohol" groups in the second set of studies with healthy, LC, BC, and PC participants.

doi:10.1371/journal.pone.0057081.g004
Figure 5. PLA2 activities were not significantly different between male and female. PLA2 activity comparison in males and females in the healthy and CRC groups. A. PLA2 activity comparison in males and females in the healthy and other cancer groups. Data from all subjects in each set of studies are also presented.
doi:10.1371/journal.pone.0057081.g005
For BC versus healthy control, the AUC = 0.8624 (Fig. 8D). In 95% of the 1000 bootstrapped sample, AUCs are higher than 0.8161.

For PC versus healthy control, the AUC = 0.8671. In 95% of the 1000 bootstrapped sample, AUCs are higher than 0.8426.
Finally, since we have found that the PLA₂ activities were essentially no difference in the two sets of healthy controls, we combined all healthy controls and all cancer cases in both sets of studies and generated a combined formula, with an AUC = 0.8011 (Fig. 8F). In 95% of the 1000 bootstrapped samples, AUCs are higher than 0.7907.

\[
\ln \left( \frac{P}{1-P} \right) = -4.6897 + 0.00263 \times PLA₂ - 0.00411 \times iPLA₂ + 0.00263 \times cPLA₂ + 0.00342 \times sPLA₂
\]
Table 6. Comparison of two independent sets of healthy controls.

|                     | 1st set |         | 2nd set |         | P value |
|---------------------|---------|---------|---------|---------|---------|
| Gender              |         |         |         |         |         |
| Male                | 31      | 40.3    | 61      | 77.2    | <0.0001 |
| Female              | 46      | 59.7    | 18      | 22.8    |         |
| Smoking status      |         |         |         |         |         |
| Current smoker      | 2       | 3.8     | 4       | 5.1     | 0.889   |
| Past smoker         | 19      | 35.8    | 25      | 31.6    |         |
| Never smoked        | 32      | 60.4    | 50      | 63.3    |         |
| Second hand smoke   |         |         |         |         | <0.0001 |
| No                  | 48      | 90.6    | 32      | 40.5    |         |
| Yes                 | 5       | 9.4     | 47      | 59.5    |         |
| Alcohol             |         |         |         |         | <0.0001 |
| No                  | 6       | 11.3    | 23      | 29.6    |         |
| Yes                 | 47      | 88.4    | 56      | 70.4    |         |
| Age (Mean ± SD)     | 51.6±13.5 | 42.7±12.03 | <0.0001 |         |
| PLA2 activities(Mean ± SD) |     |         |         |         |         |
| PLA2                | 1135.9±266.2 | 1156.3±311.8 | 0.660 |         |
| iPLA2               | 1082.0±286.1 | 1105.4±301.6 | 0.620 |         |
| cPLA2               | 1246.1±318.7 | 1287.8±425.9 | 0.488 |         |
| sPLA2               | 299.1±164.7 | 293.9±137.3 | 0.828 |         |

doi:10.1371/journal.pone.0057081.t006

\[
\ln \left( \frac{P_{1} - 1}{P_{1}} \right) = -3.0732 + 0.000461 \times PLA2 - 0.00131 \times iPLA2 + 0.00222 \times cPLA2 + 0.00254 \times sPLA2
\]

The sensitivities and specificities can be obtained from the ROC curves shown in Fig. 8. For the CRC set of study, 60.5% sensitivity and 77.9% of specificity were obtained (Table 7). For the 2nd set of study and the data combined for both sets, sensitivities >80% and the specificities >66% were obtained for all cases (Table 7).

The potential contributions of other factors

Although most other demographic and/or environmental factors tested were not significantly different in cancer and control groups (Figs 3–7), we tested their potential contributions to the performance when they are evaluated at individual levels. We kept all four PLA2 measurements in the models, but let other predictors subject to model selections at the significant level 0.05.

The prediction formula and the ROC curve to separate CRC from healthy subjects in the first set of study are as follows and shown in Fig. 9B, with an AUC = 0.9720.

\[
\ln \left( \frac{P_{2nd,all} - 1}{P_{2nd,all}} \right) = -6.7670 - 0.00034 \times PLA2 - 0.00193 \times iPLA2 + 0.00415 \times cPLA2 + 0.00173 \times sPLA2 + 5.3434 \times (Age \geq 50) - 3.4392 \times Alcohol + 2.8792 \times (Currently not but used to smoke)
\]

This performance was validated in 1000 bootstrapped samples. In 95% of the 1000 bootstrapped samples, AUCs are higher than 0.9625 for LC, PC, and BC combined vs. the second set of healthy controls.

The prediction formulas and the ROC curves for the separate LC, BC, and PC cases from healthy subjects in the second set of study are listed below and Figs. 9C to 9E, with AUCs >0.968, indicating high sensitivities and specificities of the tests. For LC versus healthy control, the AUC = 0.9742. In 95% of the 1000 bootstrapped sample, AUCs are higher than 0.9598.

\[
\ln \left( \frac{P_{LC} - 1}{P_{LC}} \right) = -7.5757 + 0.00136 \times PLA2 - 0.00373 \times iPLA2 + 0.00423 \times cPLA2 + 0.00207 \times sPLA2 + 4.3789 \times (Age \geq 50) - 3.4043 \times Alcohol + 4.0312 \times (Currently not but used to smoke)
\]

For BC versus healthy control, the AUC = 0.9682. In 95% of the 1000 bootstrapped sample, AUCs are higher than 0.9398.

\[
\ln \left( \frac{P_{BC} - 1}{P_{BC}} \right) = -7.6200 - 0.00424 \times PLA2 - 0.00010 \times iPLA2 + 0.00538 \times cPLA2 + 0.00292 \times sPLA2 + 5.9791 \times (Age \geq 50) - 2.9782 \times Alcohol
\]

For PC versus healthy control, the AUC = 0.9907. In 95% of the 1000 bootstrapped sample, AUCs are higher than 0.9740.

\[
\ln \left( \frac{P_{PC} - 1}{P_{PC}} \right) = -3.1927 + 0.00229 \times PLA2 - 0.00384 \times iPLA2 + 0.00179 \times cPLA2 + 0.00105 \times sPLA2 + 2.9716 \times (Age \geq 50) - 2.1084 \times Alcohol
\]

Finally, since we found that the PLA2 activities were essentially no difference in the two sets of healthy controls, we combined all healthy controls and all cancer cases in both sets of studies and generated a combined formula, with an AUC = 0.9140 [Fig. 9F]. In 95% of the 1000 bootstrapped samples, AUCs are higher than 0.9018.
The sensitivities and specificities obtained with these ROC curves with additional parameters are increased to >85% (except CRC vs. healthy cases; Table 7).

**Discussion**

In this work, we have presented the first measurements of plasma natural and subtype PLAA activities and their performances as potential markers for four different cancers, CRC, LC, BC, and PC. We have measured the PLAA activities in more than 20 blood samples with or without adding 1.2 mM calcium (the natural ionized calcium concentration in blood) to the final assay mixtures and did not detect any significant differences. Hence, we define the PLAA activities obtained without any additives as the "natural" PLAA activity. We have selected optimal conditions to measure each sub-family of PLAA activities. These modified conditions do not co-exist in the blood. Therefore, it is not surprising that the sum of the subfamily PLAA activities is greater than the "natural" PLAA activity. However, it is important to note that although modified conditions were used to obtain the activities for subfamilies of PLAA, the final results are from the natural PLAA present in the blood samples.

While the advantages of using convenient serologic markers are obvious, no reliable blood markers for any of these cancers are currently available. For CRC, developing/validating non-invasive or minimally invasive detection methods is a major focus in the field. Current methods include stool and blood tests, such as fecal immunochemical tests (FITs) and guaiac-based fecal occult blood testing (gFOBT). Although the specificity is high (>85%), these tests have a low sensitivity (<23%) for colorectal adenomas and are thus unlikely to be able to increase the early detection of CRC [20,21]. Genetic stool tests detect mutations in stool that can be found in CRC. A 21 genetic change test was found to be superior to guaiac fecal occult blood test (gFOBT) for the detection of CRC [20]. However, the sensitivity only reached 51.6% [20]. The plasma PLAA activities tests presented show promising initial results in separating healthy controls from cancer patients with sensitivities and specificities approximately 70%. The majority solid cancers are highly heterogeneous, which is one of the major reasons that any single or small set of markers can hardly detect any specific cancer with very high sensitivity and specificity. Testing the potential complementary values of other identified markers in CRC and other cancers will be of high significance.

Interestingly, our results suggest that PLAA activities are independent of several common demographic and environmental factors. In addition, we have compared 11 CRC blood samples collected before and after surgeries and found that 7 of 11 had reduced PLAA activities (26.1±10.9% reduction) and 4 of 11 had increased PLAA activities (37.7%±11.7%). Among them, disease progression data was available for only 6 subjects (3 from each group). Interestingly, all 3 subjects from the reduced PLAA activity group had chemotherapy and complete response and all 3 subjects from the increased PLAA activity group had chemotherapy and disease progression. These data were from a very limited number of subjects, but suggest that the prognostic value of PLAA activities warrants further testing. We are fully aware that our studies are limited to the cohort size and external validation in independent and larger scale studies will be critical and hope that our report will promote such studies.

**Is a marker which may detect multiple types of cancers useful?**

The answer is likely to be yes. Even after decades of efforts, the success rate in finding highly specific markers for specific cancers has been low. Prostate-specific antigen is an exception, but even the value of this marker as a screening tool in prostate cancer has been recently questioned [22]. Many tumor markers are known to affect multiple cancers. Sensitive, minimally invasive, reproducible, and cost-effective blood biomarkers to detect multiple malignancies are likely to be clinically significant and highly valuable as routine first line detection. In addition, the PLAA

**Table 7.** Sensitivities and specificities of PLAA to distinguish different cancers from healthy cases.

|                     | Without other parameters | With other parameters |
|---------------------|--------------------------|-----------------------|
|                     | Sensitivity | Specificity | Sensitivity | Specificity |
| **First set**       |             |             |             |             |
| CRC vs. Healthy     | 60.5%       | 77.9%       | 63.0%       | 75.5%       |
| **Second set**      |             |             |             |             |
| All cancer vs. healthy | 81.0%     | 67.1%       | 86.8%       | 96.2%       |
| LC vs. healthy      | 82.1%       | 67.1%       | 86.8%       | 96.2%       |
| BC vs. healthy      | 80.6%       | 77.2%       | 86.8%       | 96.2%       |
| PC vs. healthy      | 81.6%       | 77.2%       | 86.8%       | 96.2%       |
| **Combined two sets** |            |             |             |             |
| Cancer vs. healthy  | 80.2%       | 66.7%       | 83.2%       | 81.1%       |

[DOI 10.1371/journal.pone.0057081.t007]
activity test is very easy to perform in any laboratory with a fluorescent plate reader, and would be feasible to develop into an automated test. Moreover, very small amounts samples (1–10 μL of plasma) are needed to perform the test and the results can be obtained in 1–2 hrs. Additional markers or more specific modalities, such as colonoscopy or imaging are likely to be needed to detect specific cancers.

Another major advantage of the test is that it is reproducible, robust, and stable. It is well-recognized that many blood markers are sensitive to how blood samples are handled, processed, and stored. It is almost impossible to unify these procedures in the USA or anywhere in the world. Freeze-and-thaw is another well-known factor affecting marker stability. These reasons account, at least in part, for the fact that although thousands of markers have been reported in the past decades, seldom have any of them been cross-validated in different centers and moved to the clinic. We have used two completely independent sets of human plasma samples, which were processed somewhat differently (see Method for details) and show that the PLA₂ activities are highly compatible, consistent in healthy controls, and are independent of several demographic and environmental factors, making them more likely to be useful markers. More independent studies with large samples sizes need to be conducted to further evaluate the clinical significance of our finding reported here.

A potential caveat of the clinical usage of PLA₂ activity is that these enzymes are known to be involved in inflammation and may be elevated in patients with benign inflammatory diseases. This needs to be experimentally tested in clinical samples. However, there are mounting lines of evidence supporting the strong causal connections between inflammation and cancers [23]. In particular, chronic inflammation plays a pivotal role in the development of CRC in patients with inflammatory bowel disease [24]. The connection between inflammation and lung cancer has been shown not coincidental but may indeed be causal [23]. In addition, non-steroidal anti-inflammatory drugs have been associated with reduced risk to developing many types of cancers [25]. Thus, future studies on the significance of elevated PLA₂ activity in disease detection and progression prediction will be highly interesting.

Our results also strongly imply that the PLA₂ activities (which may or may not correlate to their RNA or protein expression levels) are potential targets for cancer treatment tested here. Most, if not all previous PLA₂ assays conducted in tissues or cell lines mainly focus on their expression levels using PCR and IHC, which are gene/protein specific, time-consuming, costly, and require relatively large amount of samples to cover different isoforms of PLA₂. Since there are more than 30 PLA₂s, none of the previous studies provide an overall picture of PLA₂s in any cancer. More importantly, their enzymatic activities, but not necessarily their RNA and/or protein expression levels, are directly related to the biological effects, since PLA₂ activities are well-known to be regulated post-transcriptionally [26,27]. This concept has been supported in our recent pre-clinical (mouse models) and human sample studies in ovarian cancer [16] and remain to be tested further in other cancers.

Acknowledgments

We highly appreciate the proof-reading and editing of Dr. Caryl Antalis.

Author Contributions

Conceived and designed the experiments: YX. Performed the experiments: HC. Analyzed the data: HC ZL. Contributed reagents/materials/analysis tools: EGC MVE DKR BWR NMH PJL MLJ. Wrote the paper: YX HC.

References

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10–29.
2. Khochikar MV (2011) Rationale for an early detection program for bladder cancer. Indian J Urol 27: 218–225.
3. Rice A, Plass C (2006) Lung cancer epigenetics and genetics. Int J Cancer 123: 1–7.
4. Pastorino U (2010) Lung cancer screening. Br J Cancer 102: 1601–1606.
5. Mutti A (2008) Molecular diagnosis of lung cancer: an overview of recent developments. Acta Biomed 79 Suppl 1: 11–23.
6. Cummings BS (2007) Phospholipase A2 as targets for anti-cancer drugs. Biochem Pharmacol 74: 949–959.
7. Murakami M, Taketomi Y, Sato H, Yamamoto K (2011) Secreted phospholipase A2 regulates post-transcriptional gene regulation in lung cancer. J Biochem 150: 233–253.
8. Kudo M, Murakami M (2002) Phospholipase A2 enzymes. Prostaglandins Other Lipid Mediat 68–69: 3–58.
9. Xu Y, Xiao YJ, Zhu K, Baughman LM, Lu J, et al. (2003) Unfolding the pathophysiological role of baiasive lysophospholipids. Curr Drug Targets Immune Endocr Metabol Disord 3: 23–32.
10. Sengupta S, Kim KS, Berk MP, Oates R, Escobar P, et al. (2007) Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion. Oncogene 26: 2994–2996.
11. Xu Y, Wang D, Wang Z (2009) Lipid generation and signaling in ovarian cancer. In: Stack MS, Fishman DA, editors. Cancer Treatment and Research—Ovarian cancer. 72 ed. New York, Dordrecht, Heidelberg, London: Springer. pp. 241–268.
12. Song Y, Wilkins P, Hu W, Murthy KS, Chen J, et al. (2007) Inhibition of calcium-independent phospholipase A2 suppresses proliferation and tumorigenicity of ovarian carcinoma cells. Biochem J 406: 427–436.
13. Li H, Zhao Z, Wei G, Yan L, Wang D, et al. (2010) Group VIA phospholipase A2 in both host and tumor cells is involved in ovarian cancer development. FASEB J 24: 4103–4116.
14. Sohra G, Grand D, Laslagnerie K, Stella A, Lumbrau G, et al. (2010) Exosomes account for vesicle-mediated transcellular transport of activatable phospholipases and prostaglandins. J Lipid Res 51: 2105–2120.
15. Ijichi H, Kosaka N, Ochiya T (2010) Secretory microRNAs as a versatile communication tool. Commun Integr Biol 3: 478–481.
16. Cai Q, Zhao Z, Natallia C, Yan L, Del Priore G, et al. (2012) Elevated and secreted phospholipase A2 activities as new potential therapeutic targets in human epithelial ovarian cancer. FASEB J.
17. Zhao X, Wang D, Zhao Z, Xiao Y, Sengupta S, et al. (2006) Caspase-3-dependent activation of calcium-indepdent phospholipase A2 enhances cell migration in non-apoptic ovarian cancer cells. J Biol Chem 281: 29357–29368.
18. Murakami M, Kudo M (2001) Diversity and regulatory functions of mammalian secretory phospholipases A2s. Adv Immunol 80: 1–7.
19. Subra C, Grand D, Laslagnerie K, Stella A, Lumbrau G, et al. (2010) Exosomes account for vesicle-mediated transcellular transport of activatable phospholipases and prostaglandins. J Lipid Res 51: 2105–2120.
20. Murakami M, Kudo M (2001) Diversity and regulatory functions of mammalian secretory phospholipases A2s. Adv Immunol 80: 1–7.
21. Steyerberg EW, Harrell FE, Jr., Borsboom GJ, Eijkemans MJ, Vergouwe Y, et al. (2011) Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 54: 774–781.
22. Pox C (2011) Colon Cancer Screening: Which Non-Invasive Filter Tests? Digestive Diseases 29: 56–59.
23. Wong MC, John GK, Hirai HW, Lam TY, Luk AK, et al. (2012) Changes in the choice of colorectal cancer screening tests in primary care settings from 7,045 prospectively collected surveys. Cancer Causes Control 23: 1541–1548.
24. Chou R, Crosswell JM, Dana T, Bougatsos C, Blazina I, et al. (2011) Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 155: 762–771.
25. Cho WC, Kwan CK, Yau S, So PP, Poon PC, et al. (2011) The role of inflammation in the pathogenesis of lung cancer. Expert Opin Ther Targets 15: 1127–1137.
24. Moossavi S, Bisheshari F (2012) Inflammation in sporadic colorectal cancer. Arch Iran Med 15: 166–170.
25. Vendramini-Costa DB, Carvalho JE (2012) Molecular Link Mechanisms between Inflammation and Cancer. Curr Pharm Des 18: 3831–3852.
26. Burke JE, Dennis EA (2009) Phospholipase A2 biochemistry. Cardiovasc Drugs Ther 23: 49–59.
27. Burke JE, Dennis EA (2009) Phospholipase A2 structure/function, mechanism, and signaling. J Lipid Res 50 Suppl: S237–242.